-

09:36:52 AM

AVXL Stock News

AVXL - Anavex Life Sciences Corporation

10/15/21 7:00 AM

Nasdaq : AVXL

conferences

Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

10/13/21 7:00 AM

Nasdaq : AVXL

clinical trial

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of

RHEA-AI

neutral

09/27/21 9:30 AM

Nasdaq : AVXL

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

09/27/21 7:00 AM

Nasdaq : AVXL

Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

09/20/21 7:00 AM

Nasdaq : AVXL

conferences

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

09/09/21 7:00 AM

Nasdaq : AVXL

conferences

Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

08/26/21 7:00 AM

Nasdaq : AVXL

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

Published in Scientific Reports, Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome Positron emission tomography (PET) Establishes ANAVEX®2-73’s Dose Dependent SIGMAR1 Receptor Occupancy Study

RHEA-AI

neutral

08/12/21 7:00 AM

Nasdaq : AVXL

earnings

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX ® 2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Exceeding of Enrollment Target for the Precision Medicine ANAVEX ® 2-73 (blarcamesine) Phase 2/3 AVATAR Clinical Trial in Patients

RHEA-AI

neutral

08/05/21 7:00 AM

Nasdaq : AVXL

earnings

Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of

RHEA-AI

neutral

08/04/21 7:00 AM

Nasdaq : AVXL

conferences

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s

RHEA-AI

neutral

1 2 3 4 5 6 Next

AVXL Data:

IndustryPharmaceutical Preparation Manufacturing
Websiteanavex.com
CeoChristopher Missling
Security nameAnavex Life Sciences Corporation
Issue typecs
SectorManufacturing
Sic code8731
Employees20
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address51 W 52nd St Fl 7th
StateNew York
CityNew York
Zip10019-6163
CountryUS
Phone18446893939

AVXL Description:

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.